@article{99855e0f8f314de5a27cfa3f6655257d,
title = "Clinical Characteristics and Outcomes of Cardiac Findings in Young Persons Following SARS-CoV-2 Infection",
abstract = "We studied cardiac complications in young persons with severe acute respiratory syndrome coronavirus 2. In a prospective cohort of 127 Military Health System beneficiaries 0-22 years old, 3.1% had cardiac abnormalities, all resolved within 6 months. Our findings support guidelines against routine cardiac screening in mild COVID-19 cases without cardiac symptoms.",
keywords = "COVID-19, SARS-CoV-2, cardiac outcomes, echocardiogram, electrocardiogram, pediatric COVID-19",
author = "{EPICC COVID-19 Cohort Study Group} and Jones, {Milissa U.} and Richard, {Stephanie A.} and Malloy, {Allison M.W.} and Colombo, {Rhonda E.} and Joseph May and David Saunders and Lindholm, {David A.} and Anuradha Ganesan and Ceyda Sablak and Hickey, {Patrick W.} and Dobson, {Craig P.} and Pollett, {Simon D.} and Ryan Flanagan and J. Cowden and M. Darling and S. DeLeon and D. Lindholm and A. Markelz and K. Mende and S. Merritt and T. Merritt and N. Turner and T. Wellington and S. Bazan and Love, {P. K.} and N. Dimascio-Johnson and N. Elnahas and E. Ewers and K. Gallagher and C. Glinn and U. Jarral and D. Jennings and D. Larson and K. Reterstoff and A. Rutt and A. Silva and C. West and H. Al-Eid and P. Blair and J. Chenoweth and D. Clark and J. Bowman and S. Chambers and C. Colombo and R. Colombo and C. Conlon and K. Everson and P. Faestel and T. Ferguson and R. Smith",
note = "Supported by awards from the Defense Health Program (HU00012020067) and the National Institute of Allergy and Infectious Disease (HU00011920111). The EPICC protocol was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed by the Uniformed Services University of the Health Sciences (USUHS) through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). S.D.P. reports that the Uniformed Services University (USU) Infectious Diseases Clinical Research Program (IDCRP), a US Department of Defense institution, and the Henry M. Jackson Foundation (HJF) were funded under a Cooperative Research and Development Agreement to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial sponsored by AstraZeneca. The Henry M. Jackson Foundation, in support of the USU IDCRP, was funded by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase III vaccine trial sponsored by AstraZeneca. Both trials were part of the US Government's COVID-19 response. Neither is related to the work presented here. The other authors have no conflicts of interest to disclose.",
year = "2025",
month = apr,
day = "1",
doi = "10.1097/INF.0000000000004617",
language = "English (US)",
volume = "44",
pages = "342--345",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "4",
}